A Study of YM178 in Patients With Symptomatic Overactive Bladder

• Status: Completed
• Trial end date: 2008-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Examine which dose of YM178 is the best in terms of efficacy, safety and tolerability compared to placebo

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Treatments: Mirabegron

Criteria

Inclusion Criteria:

• Patients over 20 years suffering from overactive bladder

Exclusion Criteria:

• Pregnant and breastfeeding women

• Any clinically significant abnormal conditions which in the opinion of the investigator makes the patient unsuitable for the study